What Nicorandil Treats: Main Uses and Benefits

Nicorandil is commonly used in the therapeutic domain of stable angina pectoris, a condition where the heart muscle receives insufficient blood flow. It is primarily applied across domains where additional symptomatic support is needed to address the burden of chronic stable angina. The medication is applied in situations involving certain distressing symptoms, generally when previous symptomatic management has been insufficient or not tolerated.

The medication may assist with managing symptoms related to physical discomfort, commonly used for symptomatic relief from angina pectoris and related chest discomfort. It is relevant for managing symptoms that interfere with daily comfort, encompassing both effort-induced angina and rest/variant angina. The application is aligned with therapeutic areas involving symptom management, which supports patients during difficult episodes by easing distress.

This supportive relief is helpful in situations where symptoms become more noticeable and may assist with maintaining functional stability during symptomatic periods.

---

Quick Fact: Relief for Angina
Primary Symptom Targeted: Chest pain/discomfort (Angina Pectoris).
Typical Context of Use: Applied in situations when supportive symptom management is appropriate for chronic, inadequately controlled stable angina.
Patient Benefit: Supports patients in coping more steadily and managing functional stability.

Nicorandil is approved for use in adult patients for the symptomatic management of stable angina pectoris. Its eligibility profile, based on official regulatory documents, is strictly defined by absolute prohibitions and special population restrictions.

Contraindicated Populations

Use of Nicorandil is absolutely contraindicated in the following groups:

Contraindication	Basis
Cardiovascular/Hemodynamic Instability	Patients with cardiogenic shock, severe hypotension, left ventricular failure with low filling pressures, or hypovolaemia.
Concomitant Medication Use	Patients taking phosphodiesterase type 5 (PDE5) inhibitors (e.g., sildenafil) or soluble guanylate cyclase (sGC) stimulators (e.g., riociguat).
Hypersensitivity	Known allergy to the active substance (nicorandil) or any excipients.

Age- and Condition-Based Restrictions

Population Group	Regulatory Status
Pediatric Population	Not recommended; safety and efficacy have not been established in patients under 18 years.
Pregnancy and Lactation	Not recommended during pregnancy or while breastfeeding due to insufficient human data.
Organ Impairment	Use is permitted in patients with hepatic (liver) or renal (kidney) impairment; no special dosage adjustment is required.
Gastrointestinal Ulceration	Use requires caution in patients with a history of pre-existing gastrointestinal ulceration; discontinuation is advised if new ulcers develop.

Interactions with other medicines and products

Interaction Scope

Category	Official Regulatory Statement
Medicinal product categories with documented interactions	Phosphodiesterase 5 inhibitors, Soluble Guanylate Cyclase Stimulators, Antihypertensive Agents, Tricyclic Antidepressants, Corticosteroids, Non-Steroidal Anti-Inflammatory Drugs.
Specific interacting medicines (if explicitly listed)	Sildenafil, Tadalafil, Vardenafil, Riociguat, Cimetidine, Rifampicin, Dapoxetine, Acetylsalicylic Acid.
Mechanistic basis of interactions (only if stated in label)	Pharmacodynamic: Potentiation of hypotensive effects. Pharmacokinetic: No significant modification of Nicorandil pharmacokinetics by Cimetidine or Rifampicin.
Timing-based interaction rules (if applicable)	None Specified for mandatory dose separation. Food delays absorption but does not affect overall exposure.
Population-specific interaction notes (if applicable)	Caution advised when combining with products that may increase potassium, specifically in moderate to severe renal impairment.
Interaction-related restrictions	Absolute prohibition (contraindication) of co-administration with PDE5 inhibitors and sGC stimulators. Avoidance of alcohol is recommended.

---

Resulting Interaction Structure

Official interaction statements:

• Co-administration with Phosphodiesterase 5 inhibitors or Soluble Guanylate Cyclase stimulators is strictly contraindicated due to the risk of severe, life-threatening hypotension.
• The blood pressure lowering effect may be increased when combined with antihypertensive agents, other vasodilators, tricyclic antidepressants, or alcohol.
• Concomitant use with NSAIDs (including acetylsalicylic acid) and Corticosteroids carries an increased risk for serious gastrointestinal haemorrhage, ulceration, or perforation.
• Studies confirm that the pharmacokinetics of Nicorandil are not significantly modified by the CYP inhibitor Cimetidine or the CYP inducer Rifampicin.

Connection to the overall interaction profile: The regulatory interaction profile is defined by a critical contraindication against agents that cause severe pharmacodynamic reinforcement of vasodilation. The profile also highlights additive hypotensive risks with various medications and alcohol, alongside a heightened risk for serious gastrointestinal complications with specific anti-inflammatory agents.

Dual Mechanism: The K ATP Channel and NO Pathway

Nicorandil acts through a dual mechanism that modulates two distinct vasodilatory pathways concurrently: it serves as an agonist for ATP-sensitive potassium channels ( K ATP) and functions as a nitric oxide ( NO) donor. This single-molecule structure engages both ionic channel modulation and secondary messenger signaling ( cGMP), resulting in a broad modulation of vascular tone.

Balanced Control of Vascular Tone

Activation of the K ATP channels leads to potassium efflux and membrane hyperpolarization in arterial smooth muscle, causing arterial dilation and reducing afterload (resistance). Conversely, NO release activates the cGMP cascade, predominantly causing relaxation in venous smooth muscle, which establishes a reduction in preload (venous return). This coordinated action lowers the total mechanical work required by the heart, while its vasodilatory effect on the coronary vessels alters the flow of blood to the myocardium.

Mito- K ATP Activation and Cellular Influences

Beyond its systemic hemodynamic effects, Nicorandil's interaction with K ATP channels extends to the mitochondria of heart cells ( mito- K ATP). Modulation of these channels influences the cellular response to metabolic stress and is associated with mechanisms that alter cellular function during periods of low oxygen supply.

Nicorandil is used as an oral therapy for the long-term management of chronic stable angina, administered in a consistent, scheduled regimen according to established protocols.

Administration Principles

Instruction Domain	Official Labeled Instruction
Route and Frequency	Nicorandil is taken via the oral route as a tablet, typically administered twice daily (bid). Dosing is generally scheduled for the morning and evening.
Initial and Maintenance Dosing	Treatment commences with a usual starting dose of 10 mg twice daily. A 5 mg twice-daily starting dose may be considered for patients prone to headache. The maintenance dose is commonly 10 mg to 20 mg twice daily, and the maximum official dose is 40 mg twice daily.
Intake Conditions	Tablets must be swallowed whole with some liquid. The time of administration is independent of food intake (may be taken with or without meals). Scored tablets may be divided to aid dose adjustment or ease of swallowing.

Population and Procedural Rules

The official instructions define the use protocol for specific populations. For older adults, no special dose adjustment is required, though the lowest effective dose is often utilized. For paediatric patients, Nicorandil is generally not recommended due to a lack of established safety and efficacy data. The overall usage pattern involves an initial phase of dose titration (adjustment) to determine the long-term maintenance dose. If a dose is missed, the protocol generally involves continuing with the next scheduled dose at the usual time.

Research evidence / Overview of studies for Nicorandil

Evidence for Use in Long-Term Management of Stable Angina

Research has explored the use of Nicorandil in individuals with stable angina pectoris, a condition characterized by fluctuating or episodic manifestations of chest discomfort. Studies conducted in this area involved large-scale, controlled designs, such as Randomized Controlled Trials (RCTs), where patients taking the study drug were compared to those taking an inactive substance (placebo). These trials were used in research exploring how symptoms change over time and typically monitored patients who were also receiving other standard heart medications.

Large-scale study reports documented the specific measurements of a composite endpoint that combined cardiovascular death, non-fatal heart attack, and unplanned hospitalization due to chest pain, for the study group and the control group over the observation period. The research also documented the measured findings for unplanned hospitalization for cardiac chest pain. Research highlights changes measured during the study period concerning patients' self-reported quality of life and symptom frequency.

Evidence for Use in Acute Heart Procedures (PCI)

Nicorandil was studied for use in a specific, acute setting: the immediate treatment of patients undergoing a procedure to open blocked coronary arteries. The main outcomes research examined were surrogate endpoints, focusing on measurements related to blood flow, such as the assessment of the no-reflow phenomenon (NRP) and the size of the heart muscle injury (infarct size).

Multiple acute studies reported measurements derived from microvascular blood flow assessments and findings related to the incidence of the no-reflow phenomenon. However, when results from multiple acute studies were combined and reviewed, the data patterns for clinical outcomes within the short-term follow-up were often described as heterogeneous (inconsistent) across the trials.

What is Still Uncertain About the Research

The research provides context but not individual predictions; findings describe group patterns, and research does not determine whether an individual will respond similarly. Data for long-term outcomes spanning many years are not fully established, and data for certain groups remain insufficient, highlighting a need for more focused research on certain patient subgroups.

Key Studies & References

1. Nicorandil prevents microvascular dysfunction resulting from PCI in patients with stable angina pectoris: a randomised study

Common questions about Nicorandil (FAQ)

---

Q: Is Nicorandil a treatment that can stop an angina chest pain attack already in progress?

A: Nicorandil is primarily for the prevention and long-term management of angina, based on its intended use and time to reach maximum concentration (Tmax). Official information states its primary role is not for acute attacks.

Q: How long does it typically take for Nicorandil to start working after the first dose?

A: Regulatory data on how the medicine is absorbed indicates that the maximum concentration of Nicorandil in the blood is typically reached within 30 to 60 minutes after taking the tablet. This time corresponds to when the medicine reaches its peak concentration in the bloodstream.

Q: How long until the full effect of Nicorandil treatment is generally expected?

A: The medicine is generally expected to reach a steady-state concentration in the blood, where the full therapeutic concentration is maintained. For Nicorandil taken twice daily, regulatory studies indicate this steady state is usually achieved within 4 to 5 days (96 to 120 hours). The full therapeutic regimen is typically achieved after this period.

Q: Do common side effects like headaches and dizziness usually lessen over time?

A: Patient information often notes that common temporary side effects, such as headache and dizziness, are often noted to be transient and may lessen or resolve as the patient continues treatment. This is a common counseling point based on patient experience.

Q: Is feeling weak or dizzy a common side effect when starting Nicorandil?

A: Yes, both dizziness and a feeling of weakness are listed in the official product information as Common side effects. This means they may affect up to 1 in 10 people who take the medicine.

Q: Can Nicorandil cause ulcers in the mouth or elsewhere in the digestive system?

A: Official warnings indicate that gastrointestinal ulcerations have been reported, including the formation of ulcers in the mouth. In rare but serious cases, these ulcers have led to complications like bleeding or perforation.

Q: What is the risk of developing ulcers on the skin or in the eyes while taking Nicorandil?

A: Reports have indicated the development of ulcerations on the skin and in the eyes, including conjunctival and corneal ulcers.

Q: What are the serious signs of a potential allergic reaction to Nicorandil?

A: Signs of a potentially serious allergic reaction include swelling of the face, lips, mouth, tongue, or throat (known as Angioedema). This swelling can cause difficulty in swallowing or breathing. These signs are considered potentially serious and should be addressed promptly.

Q: Can Nicorandil be taken alongside over-the-counter anti-inflammatory drugs (NSAIDs)?

A: Official warnings advise caution when Nicorandil is used alongside Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), which include some common over-the-counter painkillers. Combining them may increase the risk of serious complications, such as gastrointestinal ulcers or bleeding, according to regulatory warnings.

Q: Is it safe to take Nicorandil with medications used for erectile dysfunction?

A: Official documents state that taking Nicorandil concurrently with phosphodiesterase 5 inhibitors (medicines for erectile dysfunction, like sildenafil) is contraindicated (should not be used). This is a safety measure due to the potential for a severe and sudden drop in blood pressure.

Q: Does Nicorandil interact with other medicines that lower blood pressure?

A: Nicorandil's blood pressure-lowering effect may be increased when used alongside other medicines that also lower blood pressure. This includes certain antihypertensive agents, tricyclic antidepressants, and other vasodilators.

Q: Can I drink alcohol while I am taking Nicorandil?

A: Official product information states that consuming alcohol may increase the blood pressure-lowering effect of Nicorandil. This combination could potentially lead to a greater reduction in blood pressure than expected.

Q: Are there any specific foods or supplements, like salt substitutes, to avoid while on Nicorandil?

A: Regulatory documents advise caution with medicines or products that increase potassium levels in the blood. This general warning suggests a need to be cautious about supplements or salt substitutes that are high in potassium due to the reported risk of high blood potassium (hyperkalaemia).

Q: Can Nicorandil be prescribed to people who have low blood pressure?

A: Nicorandil is contraindicated (should not be used) in people with severe low blood pressure (hypotension) or conditions that put them at risk of severe hypotension, such as cardiogenic shock. This is a safety measure related to the drug's known blood pressure-lowering action.

Q: Is Nicorandil a suitable option for patients with advanced stages of heart failure?

A: Nicorandil is contraindicated in patients who have certain severe heart conditions. This includes left ventricular failure with low filling pressure or heart decompensation/shock.

Q: What information is available about using Nicorandil during pregnancy?

A: Official information states that use during pregnancy is not recommended due to limited safety data in humans. Decisions regarding use are based on a clinical risk-benefit assessment.

Q: What information is available about using Nicorandil while breastfeeding?

A: The official recommendation is to avoid breastfeeding while taking Nicorandil. This is advised because it is not known if the medicine is passed into human breast milk.

Q: Does Nicorandil affect the ability to drive or operate machinery?

A: Since Nicorandil can cause side effects like dizziness or weakness, patients are officially advised to be cautious. Patients are officially warned not to drive or operate machinery until they are certain the medicine does not impair their performance.

Q: Why must Nicorandil tablets be kept in their original blister packaging?

A: Nicorandil is sensitive to moisture. Therefore, the official instructions require the tablets to be stored in their original blister packaging to protect the medicine from moisture and help maintain its quality.

Q: What is the purpose of the small, non-drug item found inside the Nicorandil blister pack?

A: The small item found inside the Nicorandil blister pack is a desiccant, or drying agent. Its purpose is to absorb moisture and help protect the tablets from humidity during storage.

Q: What happens if the desiccant (drying agent) in the Nicorandil package is accidentally swallowed?

A: The patient information leaflet provides an explicit warning: Do not swallow the drying agent. Regulatory documentation generally only provides the explicit warning: Do not swallow the drying agent.

Q: Is Nicorandil known to increase heart rate?

A: Official side effect listings include palpitations as a common reaction, meaning a very fast, uneven, or forceful heart-beat. This may affect up to 1 in 10 people.

Q: Does Nicorandil interact with other vasodilators?

A: Yes, the blood pressure-lowering effect of Nicorandil can be potentiated (increased) when it is taken at the same time as other vasodilators, which are medicines that widen blood vessels.

Q: Is Nicorandil a blood thinner, or does it work differently?

A: Nicorandil works by widening blood vessels (vasodilator action) and is not a blood thinner (anticoagulant). Regulatory data indicates that Nicorandil does not affect the anticoagulation properties of blood-thinning medicines like warfarin.

Q: Are there research studies that have examined the long-term cardio-protective effects of Nicorandil?

A: Official documentation references large studies, such as the IONA (Impact of Nicorandil in Angina) study. Research, such as the IONA study referenced in regulatory summaries, has investigated its long-term use in patients at high risk of cardiovascular events, supporting its indication.

Q: Does having a history of diverticular disease affect the safety of taking Nicorandil?

A: Nicorandil has been associated with the development of gastrointestinal ulcerations. Official warnings advise that caution should be used when prescribing Nicorandil to patients with pre-existing digestive conditions, such as diverticular disease.

Q: Can taking Nicorandil cause flushing or redness of the skin?

A: Yes, flushing or redness of the skin is listed in the official product information as a Common side effect. This means it may affect up to 1 in 10 people.

Q: Can Nicorandil interact with other medications that increase potassium levels?

A: Caution is advised in official warnings when Nicorandil is used with other medicines that may increase potassium levels in the body. Caution is advised because reports of high potassium levels (hyperkalaemia) have been observed with its use.

Q: Is Nicorandil considered a nitrate drug, similar to nitroglycerin?

A: Official documentation notes that Nicorandil acts as a nitric oxide (NO) donor as part of its dual mechanism, which has a similar effect to some nitrate-containing medicines (nitrovasodilators). However, Nicorandil also works by opening potassium channels, making its overall action distinct from traditional nitrates.

Q: Does Nicorandil have an impact on blood pressure levels?

A: According to the official product information, Nicorandil can lower blood pressure at therapeutic doses. For this reason, the medicine is contraindicated (should not be used) in patients who already have severe hypotension, which is significantly low blood pressure.

Q: Is Nicorandil generally considered safe for long-term use?

A: The official product information indicates that Nicorandil is specifically indicated for the long-term management of chronic stable angina. Research, such as the IONA study referenced in regulatory summaries, has investigated its long-term use in patients at high risk of cardiovascular events, supporting its indication.

How to Store and Dispose of Nicorandil

Nicorandil tablets require specific conditions due to their sensitivity to moisture. The medicine must be stored at a temperature below 25 C and kept in its original package to protect it from moisture. Patients must keep the tablets in the blister strip until immediate use.

Stability and Disposal

Once a blister strip is opened, the tablets within that strip must be used within 30 days.

For safety, the medication must be stored out of the sight and reach of children.

Any unused or expired product must be disposed of in accordance with local requirements for medicinal waste.